Seeking Alpha

Seeking Alpha Portfolio App for iPad

7,597 people get DNDN articles and Market Currents by email alert.

Get email alerts on DNDN »

DNDN

Dendreon Corporation

6/19/2013, 5:51 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 7, 2012, 4:39 PM Dendreon (DNDN): Q1 EPS -$0.70 misses by $0.07. Excluding $17M in cash and noncash severance expenses, EPS was -$0.59. Revenue of $82M in-line. (PR) Comment! [Earnings]
Thursday, April 19, 2012, 9:03 AM The hefty premium that Human Genome Sciences rejected from GlaxoSmithKline spills over to help lift up shares of Dendreon (DNDN), +6.7% premarket on M&A speculation. Comment! [Healthcare, On the Move]
Thursday, April 19, 2012, 9:00 AM Premarket gainers: HGSI +100%. MLNX +25%. QIHU +22%. GILD +15%. EBAY +9%. CY +8%. CVI +8%. FFIV +7%. DNDN +6%. CTIC +6%. MS +6%. BSX +5%. WOLF +4%. BACV +3%. ASML +3%.
Losers: ACHN -6%. TNP -6%. QCOM -5%. FTE -4%. EMC -3%. STD -3%. TEF -3%. Comment! [On the Move]
Thursday, April 12, 2012, 10:05 AM Citi cuts its price target on Dendreon (DNDN +0.3%) to $10 from $14 as the firm's Yaron Werber sees a "significant" threat to Provenge from rivals over the next couple of years. (Previous: Citi on DNDN) Comment! [Healthcare]
Wednesday, April 11, 2012, 9:33 AM Citigroup names Medivation (MDVN +1.1%) a Most Preferred stock and Dendreon (DNDN +0.9%) a Least Preferred stock. Citi is upbeat on Medivation’s lead product, currently known as MDV3100, designed to treat prostate cancer, while it’s cautious on prospects for Dendreon’s Provenge drug. 1 Comment [Healthcare]
Tuesday, April 3, 2012, 9:55 AM Dendreon (DNDN +1.1%) lands patent approval for a hepatitic C virus inhibitor being researched and developed with partner Schering-Plough (MRK +0.1%). 3 Comments [Healthcare]
Friday, March 30, 2012, 9:12 AM Dendreon's (DNDN) prostate cancer vaccine Provenge is under scrutiny again from longtime gadfly Marie Huber. She alleges that the studies by the company leading up to FDA approval for the drug are suspect and says she will present her finding to EU officials as they consider Provenge. 17 Comments [Healthcare]
Wednesday, March 21, 2012, 12:26 PM Dendreon (DNDN +3.6%) is rallying, apparently on takeover speculation. The drug developer also jumped last Tuesday on M&A rumors. 1 Comment [Healthcare, M&A, On the Move]
Tuesday, March 13, 2012, 10:17 AM Dendreon (DNDN +4.4%) perks up as traders line up the company as a potential target for a takeover or passive investment with its valuation down a sharp 44% from just three weeks ago. Comment! [On the Move, Healthcare]
Friday, March 9, 2012, 3:59 PM Dendreon (DNDN -0.3%) slips after Cantor lowers its price target to $12 from $14 at Cantor, citing concerns that Zytiga's positive data yesterday may create greater risk to Provenge's market penetration. 1 Comment [Healthcare]
Thursday, March 8, 2012, 10:04 AM Deutsche Bank sticks to its guns on Dendreon (DNDN -16.1%) despite the sharp selloff off of news that Johnson & Johnson's prostate cancer drug is a go. Analysts with Deutsche not only maintain a Buy rating while keeping their outlook for sales of Provenge in place, they make the call to buy shares into weakness. Comment! [Healthcare, On the Move, Quick Ideas]
Thursday, March 8, 2012, 9:57 AM More on Johnson & Johnson's (JNJ +1.3%) Zytiga success: The company expects to file for FDA approval in the second half of 2012 for the prostate cancer treatment. Shares of rival Dendreon (DNDN -16.3%) react negatively to the development, while Medivation (MDVN +9.2%) soars because it's developing a prostate cancer drug that is a close version of Zytiga. 1 Comment [Healthcare, On the Move]
Thursday, March 8, 2012, 9:00 AM Premarket gainers: MWA +18%. XOMA +8%. SQNM +7%. NBG +5%. GNOM +4%. CCI +4%. RAD +5%. MWW +4%. DB +4%. ING +4%. RIO +3%. MT +3%. BUD +3%. DRYS +3%. ARMH +3%. STO +3%. UBS +3%. SINA +3%. AEO +3%.
Losers: DNDN -13%. STP -6%. ALKS -5%. WSM -4%. AMLN -4%. MCD -3%. CIGX -3%. UAL -3%. AGNC -3%. 2 Comments [On the Move]
Thursday, March 8, 2012, 8:47 AM Word that a Zytiga phase 3 prostate cancer trial conducted by a unit of Johnson & Johnson (JNJ) was stopped early positive for efficacy creates a ripple effect with companies involved in developing prostate cancer drugs. Premarket movers: JNJ +0.7%, DNDN -15.1%, MDVN +4.4%. Comment! [Healthcare, On the Move]
Monday, February 27, 2012, 11:14 AM In spite of beating Q4 estimates, Dendreon (DNDN -16.4%) is tanking in early trading. A possible culprit is the company's guidance for a Q1 sales decline, though Street estimates had already forecast a sales drop. 1 Comment [Healthcare, On the Move]
Monday, February 27, 2012, 8:41 AM Dendreon (DNDN): Q4 GAAP EPS of $0.26, non-GAAP EPS of $0.45, vs. consensus estimate of -$0.23. Revenue of $202.1M (+208% Y/Y) beats by $81M. Shares +2.9% premarket. (PR) 12 Comments [Earnings, Healthcare]